LeadArtis is currently funded by Growth Factor Biocapital, Bionexum Ventures and other angel investors as well as with non-dilutive grants.
R&D activities, facilities and equipment have been co-financed by the Spanish Ministry of Economy and Competitiveness (Torres Quevedo Program calls 2009, 2011, 2013 and 2017) and the RETOS Collaboration program 2014 and 2016 calls; by the RIS3 innovation program from the Comunidad de Madrid regional initiative; and by the 7th European Framework Program (FP7) in addition to private funds. Additionally, we have received support by the Genoma España Foundation and by the Carlos III Health Institute.

Latest News

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research
Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models

Leadartis reaches a major milestone with the demonstration of...

Leadartis featured in EXPANSION as a ‘Start up’ that leads the fight against cancer